Moreover, HY patients expressed significantly higher levels of NR3C1 than MS and CCND1 patients (1.3-fold mean increase, p < 0.0001) (Figure 2B), which may be explained by the localization of the NR3C1 gene on chromosome 5. This evidence concerns the gene CCND1 and myeloid sarcoma.